Tofacitinib therapy for rheumatoid arthritis : a direct comparison study between biologic-naive and experienced patients.

Tofacitinib therapy for rheumatoid arthritis : a direct comparison study between biologic-naive and experienced patients. - Efficacy of tofacitinib for rheumatoid arthritis patients in Japan.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035854

Enrollment

100

Registered

2019-02-12

Start date

2014-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who met RA classification criteria (1987 ACR, 2010 ACR/EULAR). Patients have a disease activity score assesing 28 joints (CDAI) of more than 10. Patients agreed with tofacitinib therapy.

Exclusion criteria

Exclusion criteria: Patients who have previously recieved tofacitinib therapy.

Design outcomes

Primary

Measure	Time frame
CDAI Index	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactKatsunori Kokubu

NHO Kumamoto Saishunsou National Hospital secretariat

8211sy01@hosp.go.jp81-96-242-1000

Outcome results